Evidence map›Paper›PMID 25281744›Full record

ArticleThe Journal of biological chemistry2014

Cyclopamine modulates γ-secretase-mediated cleavage of amyloid precursor protein by altering its subcellular trafficking and lysosomal degradation.

Anna G Vorobyeva, Randall Lee, Sean Miller, Charles Longen, Michal Sharoni, Preeti J Kandelwal, Felix J Kim, Daniel R Marenda, Aleister J Saunders

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Intracellular protein GBF1 displays significant associations with amyloid pathology in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Review
  4. Review
  5. Pterostilbene Promotes Mean Lifespan in Both Male and FemaleOxidative medicine and cellular longevity · 2022
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna G VorobyevaFrom the Department of Biology, Drexel University, Philadelphia, Pennsylvania 19104 and.
Randall LeeFrom the Department of Biology, Drexel University, Philadelphia, Pennsylvania 19104 and.
Sean MillerFrom the Department of Biology, Drexel University, Philadelphia, Pennsylvania 19104 and.
Charles Longenthe Departments of Pharmacology and Physiology.
Michal SharoniFrom the Department of Biology, Drexel University, Philadelphia, Pennsylvania 19104 and.
Preeti J KandelwalFrom the Department of Biology, Drexel University, Philadelphia, Pennsylvania 19104 and.
Felix J Kimthe Departments of Pharmacology and Physiology.
Daniel R MarendaFrom the Department of Biology, Drexel University, Philadelphia, Pennsylvania 19104 and Neurobiology and Anatomy, and.
Aleister J SaundersFrom the Department of Biology, Drexel University, Philadelphia, Pennsylvania 19104 and Neurobiology and Anatomy, and Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102 Aleister.Saunders@drexel.edu.

Funding

Identification and Characterization of APP Metabolism RegulatorsR01NS057295 · NINDS · DREXEL UNIVERSITY · PI SAUNDERS, ALEISTER J. · 2008 to 2012
$1.6M
NINDS NIH HHS R01 NS057295NINDS NIH HHS R01NS057295
6 · The paper itself

Abstract

Alzheimer disease (AD) is a progressive neurodegenerative disease leading to memory loss. Numerous lines of evidence suggest that amyloid-β (Aβ), a neurotoxic peptide, initiates a cascade that results in synaptic dysfunction, neuronal death, and eventually cognitive deficits. Aβ is generated by the proteolytic processing of the amyloid precursor protein (APP), and alterations to this processing can result in Alzheimer disease. Using in vitro and in vivo models, we identified cyclopamine as a novel regulator of γ-secretase-mediated cleavage of APP. We demonstrate that cyclopamine decreases Aβ generation by altering APP retrograde trafficking. Specifically, cyclopamine treatment reduced APP-C-terminal fragment (CTF) delivery to the trans-Golgi network where γ-secretase cleavage occurs. Instead, cyclopamine redirects APP-CTFs to the lysosome. These data demonstrate that cyclopamine treatment decreases γ-secretase-mediated cleavage of APP. In addition, cyclopamine treatment decreases the rate of APP-CTF degradation. Together, our data demonstrate that cyclopamine alters APP processing and Aβ generation by inducing changes in APP subcellular trafficking and APP-CTF degradation.

Indexed as

Amyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAnimalsDrosophila melanogasterHeLa CellsHumansLysosomesProtein TransportProteolysistrans-Golgi NetworkVeratrum AlkaloidsAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAPP protein, humancyclopamineVeratrum AlkaloidsAlzheimer DiseaseAmyloid Precursor Protein (APP)Amyloid-β (Aβ)Intracellular TraffickingLysosomeSterolγ-Secretase

Identifiers

PMID25281744
PMCPMC4246084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.